Biopsy Testing Equipment & Supplies

The test is available in the United States, Europe, China and selected other countries. ...

AlphaLiquid® Detect is an industry-first tumor-informed, hybrid-capture NGS-based liquid biopsy test designed for MRD detection and recurrence monitoring in stage I-III solid tumor patients. The assay incorporates a personalized panel of up to 1,000 targets, including both tumor-informed patient-specific markers as well as additional therapeutic targets. ...

InVisionFirst®-Lung, a ctDNA NGS liquid biopsy testing 37 genes relevant to the care of patients with advanced NSCLC. Covered for Medicare and other private insurance NSCLC patients who meet specific clinical criteria in the United States. InVisionFirst-Lung® is available world-wide for both commercial and research use. ...

Combining Biocept’s Liquid Biopsy biomarker testing expertise with Oncomine™ from Thermo Fisher Scientific’s next-generation sequencing and decision support ...

In addition, it sequences a fixed panel of 40 genes associated with response/resistance to targeted therapies and immunotherapy, and/or frequently mutated in cancer. In 2013, OncoDNA became the first company to launch a personalized liquid biopsy ...

Our Guardant Reveal™ test is the first blood-only test that detects residual and recurrent disease in two weeks, without the need for a tissue biopsy. The test detects circulating tumor DNA (ctDNA) in blood after surgery to identify patients with residual disease who may benefit most from adjuvant therapy. ...

The company’s proprietary miR Disease Management Platform® was developed to revolutionize the standard of value-based care for cancers and initially focuses on urological cancers. The initial test delivered by the miR Disease Management Platform® is the miR Sentinel™ Prostate Cancer Test, the first and only standalone, non-invasive liquid ...

The 4Kscore® Test is used by health care professionals to improve the accuracy of prostate cancer diagnosis after an abnormal prostate-specific antigen (PSA) test result, or digital rectal exam, before the decision is made to biopsy. The 4Kscore® Test provides a risk score (4KScore) for finding aggressive prostate cancer ...

The ExoDx Prostate is a simple, non-invasive urine test that can discriminate the risk of aggressive prostate cancer (defined as Gleason Score ≥7). This test is now available as an At-Home Collection Kit that can be initiated by an electronic order signed by the physician and sent directly to the patient’s home for ...

The only exosome-based test that provides unique, actionable intelligence to help you decide if biopsy is necessary; independent of PSA and other standard of care (SOC) features. Connect with a representative in your area for more information today. ...

The completely redesigned Melody III mammography line is the best the new technologies and Villa’s experience in mammography can offer. Every aspect of the X-ray examination and every characteristic of the mammography unit have been reviewed in depth, making improvements to increase patient comfort and the examination speed and achieving even greater diagnostic accuracy and operational ...

Shifting the Paradigm of Prenatal Screening: The name of our non-invasive prenatal test (NIPT) is appropriately called “UNITY” as it brings together fetal screening for aneuploidies and recessive conditions. It also represents uniting pregnant patients in more equitable ...

Providing clarity and confidence in treatment planning. The Decipher Prostate (Decipher Prostate Biopsy and Decipher Prostate RP) genomic classifier is a 22-gene, whole-transcriptome-developed test designed to help inform treatment decisions for men with localized prostate cancer at initial diagnosis and after surgical removal of the prostate. ...

It can also be used as a tool for a high-risk screening population in combination with Low Dose Computed Tomography (LDCT). DiagnoLung identifies and measures proteins which are differentially expressed in blood samples of individuals with Lung ...

Our molecular counting platform can help quantify nearly undetectable DNA changes, unlocking improvements to non-invasive prenatal screening and liquid ...

SelectMDx Helps Physicians Determine if a Patient is at Higher or Lower Risk for Prostate Cancer and Which Men Can Safely Avoid Biopsy. A non-invasive urine test (“liquid biopsy”), SelectMDx measures the expression of two mRNA cancer-related biomarkers (HOXC6 and DLX1).1 The test provides binary results that, when ...

Starting with the Guardant360 CDx test for complete genomic profiling identifies more patients with actionable biomarkers more quickly than starting with tissue biopsy.1-3 The test covers all genes recommended by the National Comprehensive Cancer Network, including the 55 most relevant to clinical care. ...